Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

An ACE2-Fc decoy produced in glycoengineered plants neutralizes ancestral and newly emerging SARS-CoV-2 variants and demonstrates therapeutic efficacy in hamsters

  • Föderl-Höbenreich, Esther
  • Izadi, Shiva
  • Hofacker, Lara
  • Kienzl, Nikolaus F.
  • Castilho, Alexandra
  • Strasser, Richard
  • Tarrés Freixas, Ferran
  • Cantero Portillo, Guillermo
  • Roca, Núria
  • Pérez Maíllo, Mónica
  • Lorca-Oró, Cristina
  • Usai, Carla
  • Segalés, Joaquim
  • Vergara-Alert, Júlia
  • Mach, Lukas
  • Zatloukal, Kurt
Newly emerging SARS-CoV-2 variants of concern (VOCs) continue to drive COVID-19 waves and are typically associated with immune escape and increased resistance to current therapeutics including monoclonal antibodies. By contrast, VOCs still display strong binding to the host cell receptor ACE2. Consistent with these properties, we have now found that a soluble ACE2-Fc decoy produced in glycoengineered plants effectively neutralizes different SARS-CoV-2 isolates and exhibits even increased potency against VOCs as compared to an ancestral virus strain. In a golden Syrian hamster model, therapeutic intranasal delivery of ACE2-Fc effectively reduced weight loss and SARS-CoV-2 replication in the lungs when administered 24 h post-inoculation. This protective effect was not observed upon treatment of the infected animals with a non-binding ACE2-Fc mutant, demonstrating that the plant-derived ACE2-Fc decoy interferes specifically with the attachment of the virus to host cells. The results obtained provide support for further development of decoy-based antiviral approaches by plant molecular pharming., We thank Ulrike Vavra, Katharina Wolf and David Niedermayer for assistance with ACE2-Fc purification and characterization and Vinny Kunnummel for plant propagation and maintenance. We are grateful to Florian Krammer for his advice on the design of the in vivo study. This work was supported by funds from BOKU University and a Transnational Access Grant provided by ISIDORe (funded by the European Union’s Horizon Europe research and innovation program under grant agreement No. 101046133) to Zatloukal Innovations GmbH. This research was funded in part by the Austrian Science Fund (FWF) [W 1224/Grant https://doi.org/10.55776/W1224; P 31920/Grant https://doi.org/10.55776/P31920; P 35292/Grant https://doi.org/10.55776/P35292]. For open access purposes, the authors have applied a CC BY public copyright license to any accepted manuscript version arising from this submission. The SARS-CoV-2 variant hCoV-19/France/GE1973/2020, clade G, D614G (S) was supplied through the European Virus Archive goes Global (EVAg) platform, a project that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 653316., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Seroprevalence of toscana Virus and sandfly fever sicilian virus in European bat colonies measured using a neutralization test

  • Ayhan, Nazli
  • López-Roig, Marc
  • Monastiri, Abir
  • Charrel, Rémi N.
  • Serra Cobo, Jordi
Toscana phlebovirus (TOSV) and Sicilian phlebovirus (SFSV) are endemic in the Mediterranean area where they are transmitted to humans by infected sandflies. Vertebrates of several species have been postulated to act as reservoirs of these viruses, but convincing evidence is still awaited. Among them, bats have been suggested, however documented evidence is lacking. Here we tested a total of 329 bats belonging to eight species collected from twelve localities in southern Spain for the presence of neutralizing antibodies specific to TOSV and SFSV. Positive sera were detected in Schreiber's long-fingered bat (Miniopterus schreibersii), mouse-eared Myotis (Myotis myotis), European free-tailed bat (Tadarida teniotis), and common serotine (Eptesicus serotinus) with the latter showing the highest prevalence rates for SFSV (22.6%) and TOSV (10%). There was no difference between females and males. Results suggest that bats are not likely to play a major role in the natural cycle of these two sandfly-borne phleboviruses. However, large breeding colonies of bats can be used as sentinels for surveillance of the presence of such viruses in a given locality. In addition, capture-recapture studies should be initiated in order to understand better the dynamics of TOSV and SFSV in bat populations.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tick-borne pathogens induce differential expression of genes promoting cell survival and host resistance in Ixodes ricinus cells

  • Mansfield, Karen L.
  • Cook, Charlotte
  • Ellis, Richard J.
  • Bell-Sakyi, Lesley
  • Johnson, Nicholas
  • Alberdi, Pilar
  • Fuente, José de la
  • Fooks, Anthony R.
[Background]: There has been an emergence and expansion of tick-borne diseases in Europe, Asia and North America in recent years, including Lyme disease, tick-borne encephalitis and human anaplasmosis. The primary vectors implicated are hard ticks of the genus Ixodes. Although much is known about the host response to these bacterial and viral pathogens, there is limited knowledge of the cellular responses to infection within the tick vector. The bacterium Anaplasma phagocytophilum is able to bypass apoptotic processes in ticks, enabling infection to proceed. However, the tick cellular responses to infection with the flaviviruses tick-borne encephalitis virus (TBEV) and louping ill virus (LIV), which cause tick-borne encephalitis and louping ill respectively, are less clear. [Results]: Infection and transcriptional analysis of the Ixodes ricinus tick cell line IRE/CTVM20 with the viruses LIV and TBEV, and the bacterium A. phagocytophilum, identified activation of common and distinct cellular pathways. In particular, commonly-upregulated genes included those that modulate apoptotic pathways, putative anti-pathogen genes, and genes that influence the tick innate immune response, including selective activation of toll genes. [Conclusion]: These data provide an insight into potential key genes involved in the tick cellular response to viral or bacterial infection, which may promote cell survival and host resistance., This work was jointly funded by the European Commission Seventh Framework Programme under ANTIGONE (project 278976), the Department for Environment, Food and Rural Affairs (Defra), Scottish Government and Welsh Government under project SE4112, EUH2020-funded Research Infrastructure Grant 'European Virus Archive Global (EVAg)' (H2020 grant agreement number 653316) and the INIA grant E-RTA2013-C04-04 (FEDER cofunded, Spain). Lesley Bell-Sakyi is supported by the United Kingdom Biotechnology and Biological Sciences Research Council’s Institute Strategic Programme Grant (BBS/E/I/0000174) to the Pirbright Institute., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection

  • Stalin Raj, V.
  • Okba, Nisreen M. A.
  • Gutierrez-Alvarez, Francisco J.
  • Drabek, Dubravka
  • Dieren, Brenda van
  • Widagdo, W.
  • Lamers, Mart M.
  • Widjaja, Ivy
  • Fernandez-Delgado, Raúl
  • Solá Gurpegui, Isabel
  • Bensaid, Albert
  • Koopmans, Marion P.
  • Segalés, Joaquim
  • Osterhaus, Albert D. M. E.
  • Bosch, Berend Jan
  • Enjuanes Sánchez, Luis
  • Haagmans, Bart L.
Middle East respiratory syndrome coronavirus (MERS-CoV) continues to cause outbreaks in humans as a result of spillover events from dromedaries. In contrast to humans, MERS-CoV¿exposed dromedaries develop only very mild infections and exceptionally potent virus-neutralizing antibody responses. These strong antibody responses may be caused by affinity maturation as a result of repeated exposure to the virus or by the fact that dromedaries¿ apart from conventional antibodies¿have relatively unique, heavy chain¿only antibodies (HCAbs)., This study was financed by a grant from the Zoonotic Anticipation and Preparedness Initiative [ZAPI project; Innovative Medicines Initiative (IMI) grant agreement no. 115760], with the assistance and financial support of IMI and the European Commission, and in-kind contributions from European Federation of Pharmaceutical Industries and Associations partners. A part of the study was supported by the European Virus Archive Goes Global project, which received a grant from the European Union Horizon 2020 Framework Program for Research and Innovation (653316) and grants from the Ministry of Science and Innovation of Spain (Bio2016-75549-R AEI/FEDER, UE) and NIH (2PO1AIO6O699)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group

  • Gorbalenya, Alexander E.
  • Baker, Susan C.
  • Baric, Ralph
  • Groot, Raoul J. de
  • Drosten, Christian
  • Gulyaeva, Anastasia A.
  • Haagmans, Bart L.
  • Lauber, Chris
  • Leontovich, Andrey M.
  • Neuman, Benjamin W.
  • Penzar, Dmitry
  • Perlman, Stanley
  • Poon, Leo
  • Samborskiy, Dmitry
  • Sidorov, Igor A.
  • Solá Gurpegui, Isabel
  • Ziebuhr, John
Publicado en Nature Microbiology (doi: 10.1038/s41564-020-0695-z) http://hdl.handle.net/10261/213002, The present outbreak of lower respiratory tract infections, including respiratory distress syndrome, is the third spillover, in only two decades, of an animal coronavirus to humans resulting in a major epidemic. Here, the Coronavirus Study Group (CSG) of the International Committee on Taxonomy of Viruses, which is responsible for developing the official classification of viruses and taxa naming (taxonomy) of the Coronaviridae family, assessed the novelty of the human pathogen tentatively named 2019-nCoV. Based on phylogeny, taxonomy and established practice, the CSG formally recognizes this virus as a sister to severe acute respiratory syndrome coronaviruses (SARS-CoVs) of the species Severe acute respiratory syndrome-related coronavirus and designates it as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To facilitate communication, the CSG further proposes to use the following naming convention for individual isolates: SARS-CoV-2/Isolate/Host/Date/Location. The spectrum of clinical manifestations associated with SARS-CoV-2 infections in humans remains to be determined. The independent zoonotic transmission of SARS-CoV and SARS-CoV-2 highlights the need for studying the entire (virus) species to complement research focused on individual pathogenic viruses of immediate significance. This research will improve our understanding of virus-host interactions in an ever-changing environment and enhance our preparedness for future outbreaks., Work on DEmARC advancement and coronavirus and nidovirus taxonomies was supported by the EU Horizon2020 EVAg 653316 project, the LUMC MoBiLe program and a Mercator Fellowship by the Deutsche Forschungsgemeinschaft (to AEG) in the context of the SFB1021 (A01 to JZ), No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

  • Gorbalenya, Alexander E.
  • Baker, Susan C.
  • Baric, Ralph
  • Groot, Raoul J. de
  • Drosten, Christian
  • Gulyaeva, Anastasia A.
  • Haagmans, Bart L.
  • Lauber, Chris
  • Leontovich, Andrey M.
  • Neuman, Benjamin W.
  • Penzar, Dmitry
  • Perlman, Stanley
  • Poon, Leo
  • Samborskiy, Dmitry
  • Sidorov, Igor A.
  • Solá Gurpegui, Isabel
  • Ziebuhr, John
Versión preprint diponible en BioRxiv (doi: 10.1101/2020.02.07.937862) http://hdl.handle.net/10261/212994, The present outbreak of a coronavirus-associated acute respiratory disease called coronavirus disease 19 (COVID-19) is the third documented spillover of an animal coronavirus to humans in only two decades that has resulted in a major epidemic. The Coronaviridae Study Group (CSG) of the International Committee on Taxonomy of Viruses, which is responsible for developing the classification of viruses and taxon nomenclature of the family Coronaviridae, has assessed the placement of the human pathogen, tentatively named 2019-nCoV, within the Coronaviridae. Based on phylogeny, taxonomy and established practice, the CSG recognizes this virus as forming a sister clade to the prototype human and bat severe acute respiratory syndrome coronaviruses (SARS-CoVs) of the species Severe acute respiratory syndrome-related coronavirus, and designates it as SARS-CoV-2. In order to facilitate communication, the CSG proposes to use the following naming convention for individual isolates: SARS-CoV-2/host/location/isolate/date. While the full spectrum of clinical manifestations associated with SARS-CoV-2 infections in humans remains to be determined, the independent zoonotic transmission of SARS-CoV and SARS-CoV-2 highlights the need for studying viruses at the species level to complement research focused on individual pathogenic viruses of immediate significance. This will improve our understanding of virus–host interactions in an ever-changing environment and enhance our preparedness for future outbreaks., Work on DEmARC advancement and coronavirus and nidovirus taxonomies was supported by the EU Horizon 2020 EVAg 653316 project and the LUMC MoBiLe program (to A.E.G.), and on coronavirus and nidovirus taxonomies by a Mercator Fellowship by the Deutsche Forschungsgemeinschaft (to A.E.G.) in the context of the SFB1021 (A01 to J.Z.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Rapid and direct quantification of the SARS-CoV-2 virus with an ultrasensitive nanobody-based photonic nanosensor

  • Ruiz-Vega, Gisela
  • Soler, María
  • Estévez, M. Carmen
  • Ramirez-Priego, Patricia
  • Pazos, Martalu D.
  • Noriega, María A.
  • Margolles, Yago
  • Francés-Gómez, Clara
  • Geller, Ron
  • Matusali, Giulia
  • Colavita, Francesca
  • Di Caro, Antonino
  • Casasnovas, José María
  • Fernández, Luis Ángel
  • Lechuga, Laura M.
The coronavirus (CoV) disease 2019 (COVID-19) is expected to become endemic in the coming years, meaning that the worldwide society shall be prepared to routinely manage the highly contagious respiratory SARS-CoV-2. A rapid and early diagnosis of the SARS-CoV-2 infection is crucial for controlling the spread of the disease, interrupting the transmission chain, and providing timely medical attention to patients. We introduce an innovative nanophotonic biosensor for the quantitative detection of viral particles in less than 20 minutes total assay time. The nanosensor, based on the bimodal waveguide (BiMW) interferometric technology, has been functionalized with novel bioengineered nanobodies (Nb) targeting the SARS-CoV-2 receptor-binding domain (RBD). Our approach relies on the direct capture of the viral particles, and the optimized methodology allows the detection of the SARS-CoV-2 virus with outstanding sensitivity, below 200 TCID50 per mL, being able to provide accurate viral load determination within a broad dynamic range (102–106 TCID50 per mL). Both the nanobodies and the sensor nanotechnology can be produced at a large scale with highly-efficient cost-effective procedures, and they are being integrated into a user-friendly point-of-care device for multiplexed and decentralized operation. The implementation of this unique biosensor in primary care assistance, hospitals, pharmacies, or private laboratories could greatly aid in the relief and descongestion of the sanitary systems and the clinical and social management of COVID-19., This work has been mainly funded by the H2020 Research and Innovation Program of the European Commission (H2020-SC1-PHE-Coronavirus-2020, CONVAT No 101003544) and by the European Commission – NextGenerationEU (Regulation EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global – Iniciativa Estratégica de Diagnóstico). The ICN2 is funded by the CERCA Program/Generalitat de Catalunya and supported by the Severo Ochoa Centers of Excellence program, funded by the Spanish Research Agency (AEI, grant SEV-2017-0706). Work in CNB-CSIC was funded by the Spanish Ministry of Science and Innovation (MICIN) and the Spanish Research Council (CSIC) under grants PIE-RD-COVID 19 (No 202020E079) and PTI Salud Global REC_EU (No SGL 2103051, NextGenerationEU). Work at I2SysBio was funded by Ayudas de concesión directa a soluciones científico-innovadoras directamente relacionadas con la lucha contra la Covid-19 grant from the Generalitat Valenciana, Spanish National Research Council grant CSIC-COV19-082/104, Fondo Supera Covid-19 grant BlockAce, and European Commission – NextGenerationEU to Ron Geller. INMI received funds for this study from the Ministero della Salute (Ricerca Corrente - linea 1), the European Commission – Horizon 2020 (EU project 101003544 – CoNVat) and the European Virus Archive – GLOBAL (grants no. 653316 and no. 871029), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2

  • Lázaro-Gorines, Rodrigo
  • Pérez Ramírez, Patricia
  • Heras-Murillo, Ignacio
  • Adán-Barrientos, Irene
  • Albericio, Guillermo
  • Astorgano, David
  • Flores, Sara
  • Luczkowiak, Joanna
  • Labiod, Nuria
  • Harwood, Seandean Lykke
  • Segura-Tudela, Alejandro
  • Rubio-Pérez, Laura
  • Nugraha, Yudhi
  • Shang, Xiaoran
  • Li, Yuxing
  • Alfonso, Carlos
  • Adipietro, Kaylin A.
  • Abeyawardhane, Dinendra L.
  • Navarro, Rocío
  • Compte, Marta
  • Yu, Wenbo
  • MacKerell Jr., Alexander D.
  • Sanz, Laura
  • Weber, David J.
  • Blanco, Francisco J.
  • Esteban, Mariano
  • Pozharski, Edwin
  • Godoy-Ruiz, Raquel
  • Muñoz, Inés G.
  • Delgado, Rafael
  • Sancho, David
  • García-Arriaza, Juan
  • Álvarez-Vallina, Luis
17 p.-4 fig., Administration of neutralizing antibodies (nAbs) has proved to be effective by providing immediate protection against SARS-CoV-2. However, dual strategies combining virus neutralization and immune response stimulation to enhance specific cytotoxic T cell responses, such as dendritic cell (DC) cross-priming, represent a promising field but have not yet been explored. Here, a broadly nAb, TNT, are first generated by grafting an anti-RBD biparatopic tandem nanobody onto a trimerbody scaffold. Cryo-EM data show that the TNT structure allows simultaneous binding to all six RBD epitopes, demonstrating a high-avidity neutralizing interaction. Then, by C-terminal fusion of an anti-DNGR-1 scFv to TNT, the bispecific trimerbody TNTDNGR-1 is generated to target neutralized virions to type 1 conventional DCs (cDC1s) and promote T cell cross-priming. Therapeutic administration of TNTDNGR-1, but not TNT, protects K18-hACE2 mice from a lethal SARS-CoV-2 infection, boosting virus-specific humoral responses and CD8+ T cell responses. These results further strengthen the central role of interactions with immune cells in the virus-neutralizing antibody activity and demonstrate the therapeutic potential of the Fc-free strategy that can be used advantageously to provide both immediate and long-term protection against SARS-CoV-2 and other viral infections., SARS-CoV-2 B.1.351 and B.1.167.2 viruses used in this study were obtained through the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 653316. SARS-CoV-2 B.1 (MAD6 isolate) was kindly provided by José M. Honrubia and Luis Enjuanes (CNB-CSIC, Madrid, Spain). The authors thank Centro de Investigación en Sanidad Animal (CISA)-Instituto Nacional de Investigaciones Agrarias (INIA-CSIC) (Valdeolmos, Madrid, Spain) for the BSL-3 facilities. Research in LA-V laboratory was funded by the BBVA Foundation (Ayudas Fundación BBVA a Equipos de Investigación Científica SARS-CoV-2 y COVID-19); the MCIN/AEI/10.13039/501100011033 (PID2020-117323RB-I00 and PDC2021-121711-I00), partially supported by the European Regional Development Fund (ERDF); the Carlos III Health Institute (ISCIII) (DTS20/00089), partially supported by the ERDF, the Spanish Association Against Cancer (AECC 19084); the CRIS Cancer Foundation (FCRIS-IFI-2018 and FCRIS-2021-0090), the Fundación Caixa-Health Research (HR21-00761 project IL7R_LungCan), and the Comunidad de Madrid (P2022/BMD-7225 NEXT_GEN_CART_MAD-CM). Work in the DS laboratory was funded by the CNIC; the European Union's Horizon 2020 research and innovation program under grant agreement ERC-2016-Consolidator Grant 725091; MCIN/AEI/10.13039/501100011033 (PID2019-108157RB); Comunidad de Madrid (B2017/BMD-3733 Immunothercan-CM); Atresmedia (Constantes y Vitales prize); Fondo Solidario Juntos (Banco Santander); and “La Caixa” Foundation (LCF/PR/HR20/00075). The CNIC was supported by the ISCIII, the MCIN and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MCIN/AEI/10.13039/501100011033). Research in RD laboratory was supported by the ISCIII (PI2100989) and CIBERINFEC; the European Commission Horizon 2020 Framework Programme (grant numbers 731868 project VIRUSCAN FETPROACT-2016, and 101046084 project EPIC-CROWN-2); and the Fundación Caixa-Health Research (grant number HR18-00469 project StopEbola). Research in CNB-CSIC laboratory was funded by Fondo Supera COVID-19 (Crue Universidades-Banco Santander) grant, CIBERINFEC, and Spanish Research Council (CSIC) grant 202120E079 (to J.G.-A.), CSIC grant 2020E84 (to M.E.), MCIN/AEI/10.13039/501100011033 (PID2020-114481RB-I00 to J.G-A. and M.E.), and by the European Commission-NextGenerationEU, through CSIC's Global Health Platform (PTI Salud Global) to J.G.-A. and M.E. Work in the CIB-CSIC laboratory was supported by MCIN/AEI/10.13039/501100011033 (PID2019-104544GB-I00 and 2023AEP105 to CA, and PID2020-113225GB-I00 to F.J.B.). Cryo-EM data were collected at the Maryland Center for Advanced Molecular Analyses which was supported by MPOWER (The University of Maryland Strategic Partnership). I.H.-M. receives the support of a fellowship from la Caixa Foundation (ID 100010434, fellowship code: LCF/BQ/IN17/11620074) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 71367. L.R.-P. was supported by a predoctoral fellowship from the Immunology Chair, Universidad Francisco de Vitoria/Merck., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Comprehensive profiling of neutralizing polyclonal sera targeting coxsackievirus B3

  • Álvarez-Rodríguez, Beatriz
  • Buceta, Javier
  • Geller, Ron
Despite their fundamental role in resolving viral infections, our understanding of how polyclonal neutralizing antibody responses target non-enveloped viruses remains limited. To define these responses, we obtained the full antigenic profile of multiple human and mouse polyclonal sera targeting the capsid of a prototypical picornavirus, coxsackievirus B3. Our results uncover significant variation in the breadth and strength of neutralization sites targeted by individual human polyclonal responses, which contrasted with homogenous responses observed in experimentally infected mice. We further use these comprehensive antigenic profiles to define key structural and evolutionary parameters that are predictive of escape, assess epitope dominance at the population level, and reveal a need for at least two mutations to achieve significant escape from multiple sera. Overall, our data provide a comprehensive analysis of how polyclonal sera target a non-enveloped viral capsid and help define both immune dominance and escape at the population level., This publication was supported by the European Virus Archive goes Global (EVAg) project that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 653316. Finally, the authors would like to acknowledge the use of the Principe Felipe Research Center (CIPF) server which was co-financed by the European Union through the Operativa Program of the European Regional Development Fund (ERDF/FEDER) of the Comunitat Valenciana 2014–2020. This work was supported by grants to R.G. from the Spanish Ministerio de Ciencia y Innovacion (grants BFU2017-86094-R and PID2021-125063NB-I00), the Generalitat Valenciana (grant AICO/2020/216), and the European Commission NextGenerationEU fund through Consejo Superior de Investigaciones Científicas (CSIC’s) Global Health Platform (Plataforma Temática Interdisciplinar, PTI Salud Global). B.A.-R. holds a Generalitat Valenciana postdoctoral fellowship (APOSTD/2021/017). J.B. acknowledges support from the Spanish Ministry of Science and Innovation through grants PID2022-137436NB-I00 and PID2019- 105566GB-I00 and from the LifeHUB Research Network through grant PIE-202120E047-Conexiones-Life (CSIC)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Evidence for infection but not transmission of Zika virus by Aedes albopictus (Diptera: Culicidae) from Spain

  • Hernández-Triana, Luis M.
  • Barrero, Elsa
  • Delacour-Estrella, Sarah
  • Ruiz-Arrondo, Ignacio
  • Lucientes, Javier
  • Fernández de Marco, María del Mar
  • Thorne, Leigh
  • Lumley, Sarah
  • Johnson, Nicholas
  • Mansfield, Karen L.
  • Fooks, Anthony R.
Background: A number of mosquito-borne viruses such as dengue virus (DENV), Usutu virus (USUV), West Nile virus (WNV) are autochthonously transmitted in Europe and six invasive mosquito species have been detected in this temperate region. This has increased the risk for the emergence of further mosquito-borne diseases. However, there is a paucity of information on whether European populations of invasive mosquito species are competent to transmit arboviruses. In this study, the susceptibility of Aedes albopictus originating from Spain and a laboratory-adapted colony of Aedes aegypti, was assessed for infection with, and transmission of Zika virus (ZIKV). Vertical transmission in both species was also assessed. Methods: Aedes albopictus colonised from eggs collected in Spain and an existing colony of Ae. aegypti were fed infectious blood meals containing ZIKV (Polynesian strain) at 1.6 × 10 7 PFU/ml. Blood-fed mosquitoes were separated and maintained at 20 °C or 25 °C. Legs, saliva and bodies were sampled from specimens at 7, 14 and 21 days post-infection (dpi) in order to determine infection, dissemination and transmission rates. All samples were analysed by real-time RT-PCR using primers targeting the ZIKV NS1 gene. Results: At 14 dpi and 21 dpi, ZIKV RNA was detected in the bodies of both species at both temperatures. However, live virus only was detected in the saliva of Ae. aegypti at 25 °C with a transmission rate of 44%. No evidence for virus expectoration was obtained for Ae. albopictus under any condition. Notably, ZIKV RNA was not detectable in the saliva of Ae. aegypti at 20 °C after 21 days. No vertical transmission of ZIKV was detected in this study. Conclusions: Experimental infection of Ae. albopictus colonized from Spain with ZIKV did not result in expectoration of virus in saliva in contrast to results for Ae. aegypti. No evidence of vertical transmission of virus was observed in this study. This suggests that this strain of Ae. albopictus is not competent for ZIKV transmission under the conditions tested. © 2019 The Author(s).
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Surveillance of Mosquitoes (Diptera, Culicidae) in a Northern Central Region of Spain: Implications for the Medical Community

  • Ruiz Arrondo, Ignacio
  • McMahon, Barry J.
  • Hernández Triana, Luis M
  • Santibañez, Paula
  • Portillo, Aránzazu
  • Oteo, José Antonio
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

An ACE2-Fc decoy produced in glycoengineered plants neutralizes ancestral and newly emerging SARS-CoV-2 variants and demonstrates therapeutic efficacy in hamsters

  • Föderl-Höbenreich, Esther
  • Izadi, Shiva
  • Hofacker, Lara
  • Kienzl, Nikolaus F.
  • Castilho, Alexandra
  • Strasser, Richard
  • Tarrés Freixas, Ferran
  • Cantero Portillo, Guillermo
  • Roca, Núria
  • Pérez Maíllo, Mónica
  • Lorca-Oró, Cristina
  • Usai, Carla
  • Segalés, Joaquim
  • Vergara-Alert, Júlia
  • Mach, Lukas
  • Zatloukal, Kurt
Newly emerging SARS-CoV-2 variants of concern (VOCs) continue to drive COVID-19 waves and are typically associated with immune escape and increased resistance to current therapeutics including monoclonal antibodies. By contrast, VOCs still display strong binding to the host cell receptor ACE2. Consistent with these properties, we have now found that a soluble ACE2-Fc decoy produced in glycoengineered plants effectively neutralizes different SARS-CoV-2 isolates and exhibits even increased potency against VOCs as compared to an ancestral virus strain. In a golden Syrian hamster model, therapeutic intranasal delivery of ACE2-Fc effectively reduced weight loss and SARS-CoV-2 replication in the lungs when administered 24 h post-inoculation. This protective effect was not observed upon treatment of the infected animals with a non-binding ACE2-Fc mutant, demonstrating that the plant-derived ACE2-Fc decoy interferes specifically with the attachment of the virus to host cells. The results obtained provide support for further development of decoy-based antiviral approaches by plant molecular pharming., We thank Ulrike Vavra, Katharina Wolf and David Niedermayer for assistance with ACE2-Fc purification and characterization and Vinny Kunnummel for plant propagation and maintenance. We are grateful to Florian Krammer for his advice on the design of the in vivo study. This work was supported by funds from BOKU University and a Transnational Access Grant provided by ISIDORe (funded by the European Union’s Horizon Europe research and innovation program under grant agreement No. 101046133) to Zatloukal Innovations GmbH. This research was funded in part by the Austrian Science Fund (FWF) [W 1224/Grant https://doi.org/10.55776/W1224; P 31920/Grant https://doi.org/10.55776/P31920; P 35292/Grant https://doi.org/10.55776/P35292]. For open access purposes, the authors have applied a CC BY public copyright license to any accepted manuscript version arising from this submission. The SARS-CoV-2 variant hCoV-19/France/GE1973/2020, clade G, D614G (S) was supplied through the European Virus Archive goes Global (EVAg) platform, a project that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 653316., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Seroprevalence of toscana Virus and sandfly fever sicilian virus in European bat colonies measured using a neutralization test

  • Ayhan, Nazli
  • López-Roig, Marc
  • Monastiri, Abir
  • Charrel, Rémi N.
  • Serra Cobo, Jordi
Toscana phlebovirus (TOSV) and Sicilian phlebovirus (SFSV) are endemic in the Mediterranean area where they are transmitted to humans by infected sandflies. Vertebrates of several species have been postulated to act as reservoirs of these viruses, but convincing evidence is still awaited. Among them, bats have been suggested, however documented evidence is lacking. Here we tested a total of 329 bats belonging to eight species collected from twelve localities in southern Spain for the presence of neutralizing antibodies specific to TOSV and SFSV. Positive sera were detected in Schreiber's long-fingered bat (Miniopterus schreibersii), mouse-eared Myotis (Myotis myotis), European free-tailed bat (Tadarida teniotis), and common serotine (Eptesicus serotinus) with the latter showing the highest prevalence rates for SFSV (22.6%) and TOSV (10%). There was no difference between females and males. Results suggest that bats are not likely to play a major role in the natural cycle of these two sandfly-borne phleboviruses. However, large breeding colonies of bats can be used as sentinels for surveillance of the presence of such viruses in a given locality. In addition, capture-recapture studies should be initiated in order to understand better the dynamics of TOSV and SFSV in bat populations.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection

  • Stalin Raj, V.|||0000-0003-2250-8481
  • Okba, Nisreen M. A.|||0000-0002-2394-1079
  • Gutierrez-Alvarez, Javier|||0000-0003-0690-9496
  • Drabek, Dubravka
  • van Dieren, Brenda|||0000-0001-7665-683X
  • Widagdo, Widagdo
  • Lamers, Mart M.
  • Widjaja, Ivy
  • Fernandez-Delgado, Raul|||0000-0001-7411-9010
  • Sola, Isabel|||0000-0002-5704-1917
  • Bensaid, Albert|||0000-0001-6493-3756
  • Koopmans, Marion P.G|||0000-0002-5204-2312
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Osterhaus, Albert D. M. E.
  • Bosch, Berend-Jan|||0000-0002-3864-232X
  • Enjuanes, Luis|||0000-0002-0854-0226
  • Haagmans, Bart L.|||0000-0001-6221-2015
Dromedary camel heavy chain-only antibodies may provide novel intervention strategies against MERS coronavirus. Middle East respiratory syndrome coronavirus (MERS-CoV) continues to cause outbreaks in humans as a result of spillover events from dromedaries. In contrast to humans, MERS-CoV-exposed dromedaries develop only very mild infections and exceptionally potent virus-neutralizing antibody responses. These strong antibody responses may be caused by affinity maturation as a result of repeated exposure to the virus or by the fact that dromedaries-apart from conventional antibodies-have relatively unique, heavy chain-only antibodies (HCAbs). These HCAbs are devoid of light chains and have long complementarity-determining regions with unique epitope binding properties, allowing them to recognize and bind with high affinity to epitopes not recognized by conventional antibodies. Through direct cloning and expression of the variable heavy chains (VHHs) of HCAbs from the bone marrow of MERS-CoV-infected dromedaries, we identified several MERS-CoV-specific VHHs or nanobodies. In vitro, these VHHs efficiently blocked virus entry at picomolar concentrations. The selected VHHs bind with exceptionally high affinity to the receptor binding domain of the viral spike protein. Furthermore, camel/human chimeric HCAbs-composed of the camel VHH linked to a human Fc domain lacking the CH1 exon-had an extended half-life in the serum and protected mice against a lethal MERS-CoV challenge. HCAbs represent a promising alternative strategy to develop novel interventions not only for MERS-CoV but also for other emerging pathogens.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rapid and direct quantification of the SARS-CoV-2 virus with an ultrasensitive nanobody-based photonic nanosensor

  • Ruiz Vega, Gisela|||0000-0002-8438-3146
  • Soler Aznar, Maria|||0000-0001-7232-2277
  • Estévez, M. Carmen|||0000-0003-3694-7186
  • Ramirez Priego, Patricia|||0000-0001-5657-3279
  • Pazos, Martalu D.
  • Noriega, María A.
  • Margolles, Yago
  • Francés-Gómez, Clara
  • Geller, Ron
  • Matusali, Giulia
  • Colavita, Francesca
  • Caro, Antonino di
  • Casasnovas, José M.|||0000-0002-2873-6410
  • Fernández, Luis Angel
  • Lechuga, Laura M|||0000-0001-5187-5358
The coronavirus (CoV) disease 2019 (COVID-19) is expected to become endemic in the coming years, meaning that the worldwide society shall be prepared to routinely manage the highly contagious respiratory SARS-CoV-2. A rapid and early diagnosis of the SARS-CoV-2 infection is crucial for controlling the spread of the disease, interrupting the transmission chain, and providing timely medical attention to patients. We introduce an innovative nanophotonic biosensor for the quantitative detection of viral particles in less than 20 minutes total assay time. The nanosensor, based on the bimodal waveguide (BiMW) interferometric technology, has been functionalized with novel bioengineered nanobodies (Nb) targeting the SARS-CoV-2 receptor-binding domain (RBD). Our approach relies on the direct capture of the viral particles, and the optimized methodology allows the detection of the SARS-CoV-2 virus with outstanding sensitivity, below 200 TCID50 per mL, being able to provide accurate viral load determination within a broad dynamic range (102-106 TCID50 per mL). Both the nanobodies and the sensor nanotechnology can be produced at a large scale with highly-efficient cost-effective procedures, and they are being integrated into a user-friendly point-of-care device for multiplexed and decentralized operation. The implementation of this unique biosensor in primary care assistance, hospitals, pharmacies, or private laboratories could greatly aid in the relief and descongestion of the sanitary systems and the clinical and social management of COVID-19.